ReviewInternational journal of hematology2003
Biology and clinical impact of human natural killer cells.
Review in International journal of hematology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Clinical Potential of Immunotherapies in Subarachnoid Hemorrhage Treatment: Mechanistic Dissection of Innate and Adaptive Immune Responses.Aging and disease · 2023Review
- Radical gastrectomy is safe for treatment of gastric cancer patients on immunosuppressive drugs after organ transplantation.Frontiers in oncology · 2023Article
- Natural Killer Cells and Thyroid Diseases.Endocrinology and metabolism (Seoul, Korea) · 2019Review
- The latest progress on miR-374 and its functional implications in physiological and pathological processes.Journal of cellular and molecular medicine · 2019Review
- Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy.Integrative cancer therapies · 2018Article
- The biology of natural killer cells during sepsis.Immunology · 2018Review
- [Aggressive natural killer cell leukemia: study of a case occurred in Africa and literature review].The Pan African medical journal · 2018Review
- QPY/RAH haplotypes of the GZMB gene are associated with natural killer cell cytotoxicity.Immunogenetics · 2018Article
- Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report.Molecular and clinical oncology · 2017Article
- Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Article
- Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?Cancer immunology, immunotherapy : CII · 2016Review
- Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.Experimental hematology & oncology · 2013Article
- Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.Antibodies (Basel, Switzerland) · 2012Article
- NK cells in healthy aging and age-associated diseases.Journal of biomedicine & biotechnology · 2012Review
- Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Frontiers in pharmacology · 2012Article
- Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience.Current opinion in virology · 2011Review
- Bi-specific aptamers mediating tumor cell lysis.The Journal of biological chemistry · 2011Article
- Natural killer cell neoplasm: biology and pathology.International journal of hematology · 2010Review
- Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?British journal of pharmacology · 2010Review
- Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.Cancer immunology, immunotherapy : CII · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant transformation. Two subsets of human NK cells are identified according to surface CD56 expression. CD56dim cells compose the majority of NK cells and function as effectors of natural cytotoxicity and antibody-dependent cellular cytotoxicity, whereas CD56bright cells have immunomodulatory function through secretion of cytokines. For a long time, NK cells have held promise for cancer immunotherapy because, unlike T-lymphocytes, NK cells can lyse tumor cells without tumor-specific antigen recognition. To date, NK cell therapy, largely focused on in vivo expansion and activation with cytokines, has met with only modest success. However, recent understanding of the importance of NK receptors (NKR) for recognition and lysis of tumor cells while normal cells are spared suggests novel therapeutic strategies. The balance of inhibitory and activating signals through surface receptors that recognize major histocompatibility complex class I and class I-like molecules on target cells determines whether NK cells activate killing. Identification of NKR ligands and their level of expression on normal and neoplastic cells has important implications for the rational design of immunotherapy strategies for cancer. We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy.
Indexed as
Identifiers
12894845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.